Non-Hodgkin Lymphoma News

Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress

Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress

Non-Hodgkins Lymphoma Market Trends and Insights - Precedence Research

Non-Hodgkins Lymphoma Market Trends and Insights Precedence Research

The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork

The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma CancerNetwork

Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges - Cureus

Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges Cureus

ASH 2025 Updates in Non-Hodgkin Lymphoma – Binaytara - Oncodaily

ASH 2025 Updates in Non-Hodgkin Lymphoma – Binaytara Oncodaily

Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson

Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson

New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center

New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes - Yahoo Finance

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes Yahoo Finance

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature

Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 - Precedence Research

Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 Precedence Research

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma - Targeted Oncology

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma Targeted Oncology

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank - Wiley Online Library

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank Wiley Online Library

Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson

Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson

Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report - Frontiers

Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report Frontiers

A Retrospective Analysis of the Clinicopathological Spectrum and Survival Outcome of Non-Hodgkin Lymphoma From a Tertiary Care Hospital in Saudi Arabia - Cureus

A Retrospective Analysis of the Clinicopathological Spectrum and Survival Outcome of Non-Hodgkin Lymphoma From a Tertiary Care Hospital in Saudi Arabia Cureus

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma - Targeted Oncology

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma Targeted Oncology

Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature

Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature

Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma - The ASCO Post

Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma The ASCO Post

Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5 - The ASCO Post

Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5 The ASCO Post

A Milky Mystery: Chylothorax Unmasking Non-Hodgkin Lymphoma - Cureus

A Milky Mystery: Chylothorax Unmasking Non-Hodgkin Lymphoma Cureus

Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma - Cleveland Clinic

Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma Cleveland Clinic

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Nature

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Nature

Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma | JCO Precision Oncology - ASCO Publications

Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma | JCO Precision Oncology ASCO Publications